{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:53:03Z","timestamp":1762980783847,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clgc.2019.09.011","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T17:39:28Z","timestamp":1569519568000},"page":"e46-e54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-2816","authenticated-orcid":false,"given":"Takashi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Terada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-4245","authenticated-orcid":false,"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-6569","authenticated-orcid":false,"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1394-7506","authenticated-orcid":false,"given":"Shusuke","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8586-784X","authenticated-orcid":false,"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.09.011_bib1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.011_bib2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.011_bib3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.011_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.011_bib5","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/annonc\/mdv267","article-title":"Treatment of mCRPC in the AR-axis-targeted therapy-resistant state","volume":"26","author":"Chi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.09.011_bib6","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1016\/j.clgc.2016.12.015","article-title":"Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-naive metastatic castration-resistant prostate cancer","volume":"15","author":"Miyake","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.011_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/iju.13346","article-title":"Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: the Kyoto-Baltimore collaboration","volume":"24","author":"Terada","year":"2017","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.09.011_bib8","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/pros.23373","article-title":"Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer","volume":"77","author":"Mori","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2019.09.011_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clgc.2017.09.008","article-title":"Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"16","author":"Matsubara","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.011_bib10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"issue":"15 Suppl","key":"10.1016\/j.clgc.2019.09.011_bib11","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2018.36.15_suppl.5015","article-title":"Phase 2 randomized cross-over trial of abiraterone\u00a0+ prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): results for 2nd-line therapy","volume":"36","author":"Khalaf","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.011_bib12","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.011_bib13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.urolonc.2015.05.003","article-title":"Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: a tertiary academic center experience","volume":"33","author":"Afshar","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2019.09.011_bib14","doi-asserted-by":"crossref","first-page":"e1073","DOI":"10.1016\/j.clgc.2017.07.016","volume":"15","author":"Matsubara","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.011_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clgc.2017.11.007","article-title":"Comparison of alternative androgen receptor-axis-targeted agent (ARATA) and docetaxel as second-line therapy for patients with metastatic castration-resistant prostate cancer with progression after initial ARATA in real-world clinical practice in Japan","volume":"16","author":"Miyake","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.011_bib16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.eururo.2018.12.015","article-title":"Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II randomized trial","volume":"75","author":"Khalaf","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.09.011_bib17","article-title":"Genetic alterations detected in cell-free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer","volume":"3","author":"Torquato","year":"2019","journal-title":"JCO Precision Oncol"},{"key":"10.1016\/j.clgc.2019.09.011_bib18","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1038\/s41598-019-40719-y","article-title":"Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer","volume":"9","author":"Sumiyoshi","year":"2019","journal-title":"Sci Rep"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:15Z","timestamp":1761564675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319302800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1558767319302800"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.09.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}